Bank Julius Baer & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bank Julius Baer & Co’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,434	Closed	-$52K	–	586
2023 Q2	$52K	Hold	1,434	–	–	﹤0.01%	496
2023 Q1	$53K	Sell	1,434 -60	-4%	-$2.7K	﹤0.01%	513
2022 Q4	$68K	Sell	1,494 -9,953	-87%	-$644K	﹤0.01%	498
2022 Q3	$799K	Buy	11,447 +8,966	+361%	+$663K	0.01%	285
2022 Q2	$167K	Buy	2,481 +730	+42%	+$46.4K	﹤0.01%	427
2022 Q1	$144K	Buy	+1,751	New	+$179K	﹤0.01%	460
2021 Q2	–	Sell	-3,000	Closed	-$514K	–	885
2021 Q1	$514K	Sell	3,000 -1,954	-39%	-$387K	﹤0.01%	441
2020 Q4	$1.09M	Buy	4,954 +1,954	+65%	+$422K	0.01%	338
2020 Q3	$498K	Hold	3,000	–	–	﹤0.01%	387
2020 Q2	$343K	Sell	3,000 -2	-0.1%	-$194	﹤0.01%	401
2020 Q1	$231K	Buy	+3,002	New	+$269K	0.01%	385

Other funds holding MRTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank Julius Baer & Co's MRTX Position: Q3 2023 in Review

Bank Julius Baer & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 1,434 shares — an estimated $52K sold.

Bank Julius Baer & Co first reported a position in MRTX in Q1 2020 and held it in 11 quarters. The position peaked at $1.09M in Q4 2020. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Bank Julius Baer & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bank Julius Baer & Co sold 1,434 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $52K.
Bank Julius Baer & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Bank Julius Baer & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2020.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bank Julius Baer & Co's 13F filing for Q3 2023, filed 13 Nov 2023.